Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially ...
RMD Open

Birth length and perinatal exposures and rheumatoid arthritis risk in the E3N cohort

Objective To examine associations between participants’ perinatal factors, including harmonised birth weight and length, ...